A phase I study of allogeneic iPSC-derived CD19 CAR-NK with high affinity CD16 in combination with an anti-CD20 monoclonal antibody enrolled 20 patients with relapsed or refractory NHL, reporting only two cases of low-grade CRS and no ICANS or GVHD [7]. The gene discussed is CD19; the disease is non-Hodgkin lymphoma.